Target intelligence / Profile preview

Mitochondrial pyruvate carrier 1-like protein (MPC1L)

Target
MPC1L
Molecular classification
Transporter, Mitochondrial carrier protein (Metabolite transporter of the mitochondrial inner membrane)
01

Overview

Mitochondrial pyruvate carrier 1-like protein (MPC1L) is a small mitochondrial inner membrane transporter. In humans, it forms a heterodimer with the protein MPC2, creating a functional pyruvate transporter in the testes. This complex facilitates the crucial step of shuttling pyruvate from glycolysis across the mitochondrial inner membrane to the matrix, where it feeds into the tricarboxylic acid (TCA) cycle for oxidative phosphorylation and ATP production. MPC1L shares about 64% identity with the broadly expressed MPC1 and is highly tissue-specific. Structural studies show the complex operates as an alternating access transporter, utilizing specific amino acid residues for pyruvate binding and transport in a pH-dependent mechanism. The MPC complex is of pharmacological interest as a therapeutic target for metabolic diseases and some cancers, with several small molecule inhibitors developed to modulate its activity

Other names
SLC54A3Mitochondrial pyruvate carrier 1-like proteinbrain protein 44-like protein 2MPC1L
02

Mechanism of action

Competitive inhibition of pyruvate transport (drugs bind at the substrate recognition site, blocking pyruvate access)

03

Biological functions

Pyruvate transmembrane transporter activityMitochondrial pyruvate importLinks cytosolic glycolysis and mitochondrial oxidative phosphorylation
04

Disease associations

Cancer (especially those with altered mitochondrial metabolism)Diabetes mellitus (modulation of glucose utilization)Neurodegenerative diseaseMetabolic dysfunction–associated steatotic liver disease
05

Safety considerations

Targeting MPC1L/MPC2 in testes may have reproductive implications since MPC1L/MPC2 is selectively expressed in testicular tissueGeneral inhibition of MPC may disrupt cellular energy metabolism and lead to lactic acidosis or energy deficiency in non-targeted tissues
06

Interacting drugs

Zaprinast

2 more in the full profile.

Beyond the preview

Go deeper on Mitochondrial pyruvate carrier 1-like protein (MPC1L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial pyruvate carrier 1-like protein (MPC1L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call